TG Therapeutics, Inc. (NASDAQ:TGTX) stock is up on Tuesday as the company announced positive topline Phase 1 data for its subcutaneous BRIUMVI (ublituximab-xiiy) for myasthenia gravis (MG), a chronic autoimmune neuromuscular disorder that causes weakness and rapid fatigue in voluntary muscles.
This news comes during a generally positive market environment, with the S&P 500 gaining 0.3% and the Healthcare sector up 0.9%, indicating that TG Therapeutics is moving in line with broader market trends.
Subcutaneous BRIUMVI Phase 1 Data
The Phase 1 study showed that 82% of subjects achieved a minimal clinically important difference (MCID) in their MG-ADL scores, with a mean improvement of over 4 points.
The company plans to initiate a Phase 2 trial that will enroll approximately 120 patients, aiming to combine rapid symptom control with sustained disease modification.
The positive data support TG Therapeutics’ ongoing development of BRIUMVI, with FDA approval for relapsing forms of multiple sclerosis. The development could expand its market potential significantly.
Phase 3 ENHANCE Trial
In May, the biotechnology company released positive topline results from the Phase 3 ENHANCE trial evaluating a consolidated single infusion regimen for initiation of BRIUMVI for relapsing forms of multiple sclerosis.
The trial met its primary endpoint, demonstrating bioequivalent drug exposure between the currently approved BRIUMVI Day 1 and Day 15 initiation dosing and a new single infusion on Day 1 only.
The company targets a supplemental FDA application in the second half of 2026.
TG Therapeutics Technical Analysis
TGTX remains in an uptrend, but the stock looks stretched.
Shares trade 5.6% above the 20-day SMA of $39.85, 13.2% above the 50-day SMA of $37.17 and 28.1% above the 200-day SMA of $32.84. That keeps the medium- and long-term trend bullish.
The setup also remains strong. The 20-day SMA is still above the 50-day SMA. The golden cross that formed in April, when the 50-day SMA moved above the 200-day SMA, continues to support the bullish trend.
Still, momentum has cooled. MACD is below its signal line, while the histogram is negative. That suggests buying pressure has faded from the prior upswing. In plain terms, rallies may stay choppy unless buyers step back in.
Resistance sits near $44.50, just below the 52-week high of $44.65. Support is near $38, close to the rising short-term moving averages, where dip buyers may look to defend the trend.
TG Therapeutics Price Action
TGTX Stock Price Activity: TG Therapeutics shares were up 2.95% at $42.16 at the time of publication on Tuesday, according to Benzinga Pro data.
Photo via Shutterstock
Login to comment